Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for supranuclear palsy, progressive, 2 is limited due to its rarity, which affects fewer than 1 in 100,000 people worldwide. This extreme rarity results in fewer systematic clinical studies and a lack of comprehensive data. Additionally, the genetic basis of the condition has not been clearly identified, leading to ongoing challenges in clinical characterization and understanding of its full spectrum.
To navigate your care effectively, seek a neurologist with expertise in movement disorders or neurodegenerative diseases, as they will have the most relevant experience in managing conditions like PSNP2. While there are currently no identified patient organizations, you can connect with resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further support. Additionally, consider participating in clinical trials to contribute to research and potentially access new therapies. Genetic counseling may also be beneficial for understanding the implications of the autosomal dominant inheritance pattern.
Currently, there are two orphan drugs designated for the treatment of PSNP2, including a fully human IgG1k anti-PD-L1 monoclonal antibody and a recombinant humanized IgG4P monoclonal antibody with specificity for human tau. There are also four active clinical trials investigating potential treatments for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=supranuclear%20palsy%2C%20progressive%2C%202.
Actionable guidance for navigating care for supranuclear palsy, progressive, 2
To navigate your care effectively, seek a neurologist with expertise in movement disorders or neurodegenerative diseases, as they will have the most relevant experience in managing conditions like PSNP2. While there are currently no identified patient organizations, you can connect with resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further support. Additionally, consider participating in clinical trials to contribute to research and potentially access new therapies. Genetic counseling may also be beneficial for understanding the implications of the autosomal dominant inheritance pattern.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for supranuclear palsy, progressive, 2 is limited due to its rarity, which affects fewer than 1 in 100,000 people worldwide. This extreme rarity results in fewer systematic clinical studies and a lack of comprehensive data. Additionally, the genetic basis of the condition has not been clearly identified, leading to ongoing challenges in clinical characterization and understanding of its full spectrum.
To navigate your care effectively, seek a neurologist with expertise in movement disorders or neurodegenerative diseases, as they will have the most relevant experience in managing conditions like PSNP2. While there are currently no identified patient organizations, you can connect with resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further support. Additionally, consider participating in clinical trials to contribute to research and potentially access new therapies. Genetic counseling may also be beneficial for understanding the implications of the autosomal dominant inheritance pattern.
Currently, there are two orphan drugs designated for the treatment of PSNP2, including a fully human IgG1k anti-PD-L1 monoclonal antibody and a recombinant humanized IgG4P monoclonal antibody with specificity for human tau. There are also four active clinical trials investigating potential treatments for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=supranuclear%20palsy%2C%20progressive%2C%202.
Actionable guidance for navigating care for supranuclear palsy, progressive, 2
To navigate your care effectively, seek a neurologist with expertise in movement disorders or neurodegenerative diseases, as they will have the most relevant experience in managing conditions like PSNP2. While there are currently no identified patient organizations, you can connect with resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further support. Additionally, consider participating in clinical trials to contribute to research and potentially access new therapies. Genetic counseling may also be beneficial for understanding the implications of the autosomal dominant inheritance pattern.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for supranuclear palsy, progressive, 2 is limited due to its rarity, which affects fewer than 1 in 100,000 people worldwide. This extreme rarity results in fewer systematic clinical studies and a lack of comprehensive data. Additionally, the genetic basis of the condition has not been clearly identified, leading to ongoing challenges in clinical characterization and understanding of its full spectrum.
To navigate your care effectively, seek a neurologist with expertise in movement disorders or neurodegenerative diseases, as they will have the most relevant experience in managing conditions like PSNP2. While there are currently no identified patient organizations, you can connect with resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further support. Additionally, consider participating in clinical trials to contribute to research and potentially access new therapies. Genetic counseling may also be beneficial for understanding the implications of the autosomal dominant inheritance pattern.
Currently, there are two orphan drugs designated for the treatment of PSNP2, including a fully human IgG1k anti-PD-L1 monoclonal antibody and a recombinant humanized IgG4P monoclonal antibody with specificity for human tau. There are also four active clinical trials investigating potential treatments for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=supranuclear%20palsy%2C%20progressive%2C%202.
Actionable guidance for navigating care for supranuclear palsy, progressive, 2
To navigate your care effectively, seek a neurologist with expertise in movement disorders or neurodegenerative diseases, as they will have the most relevant experience in managing conditions like PSNP2. While there are currently no identified patient organizations, you can connect with resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for further support. Additionally, consider participating in clinical trials to contribute to research and potentially access new therapies. Genetic counseling may also be beneficial for understanding the implications of the autosomal dominant inheritance pattern.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.